|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current assets: | |||||||||||
| Short-term investments | |||||||||||
| Cash and cash equivalents | |||||||||||
| Short-term investments at fair value | |||||||||||
| Short-term investment at cost | |||||||||||
| Accounts receivable | |||||||||||
| Related party accounts receivable | |||||||||||
| Inventories | |||||||||||
| Prepaid inventory | |||||||||||
| Other current assets | |||||||||||
| Total current assets | |||||||||||
| Property and equipment, net | |||||||||||
| Deferred offering costs | |||||||||||
| Operating lease right-of-use assets | |||||||||||
| Goodwill and intangible assets | |||||||||||
| Other assets | |||||||||||
| Goodwill | |||||||||||
| Intangible assets, net | |||||||||||
| Unallocated purchase price provisional, Rotor Lab (See note 3) | |||||||||||
| Total non-current assets | |||||||||||
| Total assets | |||||||||||
| Current liabilities | |||||||||||
| Accounts payable and accrued expenses | |||||||||||
| Deferred revenue | |||||||||||
| Warrant liabilities | |||||||||||
| Derivative liability – convertible note conversion option | |||||||||||
| Operating lease liability | |||||||||||
| Contingent consideration | |||||||||||
| Total current liabilities | |||||||||||
| Convertible note | |||||||||||
| Deferred tax liability | |||||||||||
| Operating lease liability – less current portion | |||||||||||
| Contingent consideration | |||||||||||
| Total non-current liabilities | |||||||||||
| Total liabilities | |||||||||||
| Preferrred stock, value | |||||||||||
| Series A Preferred Stock | |||||||||||
| Series B Preferred Stock | |||||||||||
| Series C Preferred Stock | |||||||||||
| Total preferrred stock, value | |||||||||||
| Common stock - $0.01 par value, 500,000,000 authorized and 49,956,505 and 37,759,911 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively | |||||||||||
| Additional paid in capital | |||||||||||
| Accumulated deficit | |||||||||||
| Cumulative foreign currency translation adjustment | |||||||||||
| Accumulated other comprehensive income | |||||||||||
| Total stockholders’ equity | |||||||||||
| Total liabilities and stockholders’ equity |
Loading...
